SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

Alpha Teknova, Inc.
Date: July 14, 2025 · CIK: 0001850902 · Accession: 0000000000-25-007383

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288613

Date
July 14, 2025
Author
Division of
Form
UPLOAD
Company
Alpha Teknova, Inc.

Letter

Re: Alpha Teknova, Inc. Registration Statement on Form S-3 Filed July 10, 2025 File No. 333-288613 Dear Stephen Gunstream:

July 14, 2025

Stephen Gunstream President and Chief Executive Officer Alpha Teknova, Inc. 2451 Bert Drive Hollister, CA 95023

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Jason Drory at 202-551-8342 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jeff Hartlin

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 14, 2025

Stephen Gunstream
President and Chief Executive Officer
Alpha Teknova, Inc.
2451 Bert Drive
Hollister, CA 95023

 Re: Alpha Teknova, Inc.
 Registration Statement on Form S-3
 Filed July 10, 2025
 File No. 333-288613
Dear Stephen Gunstream:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Jason Drory at 202-551-8342 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Jeff Hartlin
</TEXT>
</DOCUMENT>